Last reviewed · How we verify
CI-581b
CI-581b is a dissociative anesthetic that acts as an NMDA receptor antagonist to produce rapid-onset antidepressant effects.
CI-581b is a dissociative anesthetic that acts as an NMDA receptor antagonist to produce rapid-onset antidepressant effects. Used for Treatment-resistant depression.
At a glance
| Generic name | CI-581b |
|---|---|
| Sponsor | New York State Psychiatric Institute |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
CI-581b blocks N-methyl-D-aspartate (NMDA) glutamate receptors, which disrupts excitatory neurotransmission in the brain. This mechanism is believed to rapidly alleviate depressive symptoms through downstream effects on synaptic plasticity and neuronal connectivity, distinct from traditional monoamine-based antidepressants.
Approved indications
- Treatment-resistant depression
Common side effects
- Dissociation
- Dizziness
- Nausea
- Increased blood pressure
Key clinical trials
- Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial (PHASE2)
- Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders (PHASE3)
- Facilitating Rapid Naltrexone Initiation (PHASE3)
- The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking (PHASE2)
- Glutamatergic Modulation of Disordered Alcohol Use (PHASE2, PHASE3)
- The Effect of Glutamatergic Modulation on Cocaine Self-administration (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |